An overview of normocalcemic primary hyperparathyroidism
暂无分享,去创建一个
[1] A. Palermo,et al. Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism , 2015, Osteoporosis International.
[2] G. Cevenini,et al. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. , 2015, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.
[3] Lian-tao Li,et al. Is Normocalcemic Primary Hyperparathyroidism Harmful or Harmless? , 2015, The Journal of clinical endocrinology and metabolism.
[4] Y. Greenman,et al. Letter to the editor: Thiazides are not inducers of PTH secretion: a comment on normocalcemic hyperparathyroidism. , 2015, The Journal of clinical endocrinology and metabolism.
[5] L. Rejnmark,et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. , 2014, The Journal of clinical endocrinology and metabolism.
[6] D. Borderie,et al. Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism , 2014, Osteoporosis International.
[7] D. Borderie,et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. , 2013, The Journal of clinical endocrinology and metabolism.
[8] D. Bauer,et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. , 2013, Journal of Clinical Endocrinology and Metabolism.
[9] S. Polyzos,et al. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis , 2013, Clinical endocrinology.
[10] M. Muñoz-Torres,et al. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women , 2012, Endocrine.
[11] F. Bandeira,et al. Normocalcemic versus Hypercalcemic Primary Hyperparathyroidism: More Stone than Bone? , 2012, Journal of osteoporosis.
[12] F. Keleştimur,et al. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism , 2012, Endocrine.
[13] Tracy S. Wang,et al. Surgical Management of Normocalcemic Primary Hyperparathyroidism , 2012, World Journal of Surgery.
[14] J. Aloia. The 2011 Report on Dietary Reference Intake for Vitamin D: Where Do We Go From Here? , 2011 .
[15] F. Bandeira,et al. Normocalcemic primary hyperparathyroidism in clinical practice: an indolent condition or a silent threat? , 2011, Arquivos brasileiros de endocrinologia e metabologia.
[16] N. Stern,et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. , 2010, European journal of endocrinology.
[17] L. Mosekilde,et al. Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. , 2009, The Journal of clinical endocrinology and metabolism.
[18] F. Coe,et al. New insights into the pathogenesis of idiopathic hypercalciuria. , 2008, Seminars in nephrology.
[19] M. Rubin,et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. , 2007, The Journal of clinical endocrinology and metabolism.
[20] J. Rastad,et al. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. , 2006, European journal of endocrinology.
[21] Y. Yazici,et al. Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.
[22] P. Vestergaard,et al. Effects of long‐term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover , 2005, Journal of internal medicine.
[23] Zareen Syed,et al. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. , 2004, The Journal of clinical endocrinology and metabolism.
[24] S. Silverberg,et al. "Incipient" primary hyperparathyroidism: a "forme fruste" of an old disease. , 2003, The Journal of clinical endocrinology and metabolism.
[25] P. Houillier,et al. Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. , 2003, The Journal of clinical endocrinology and metabolism.
[26] K. Kaukinen,et al. Endocrinological disorders and celiac disease. , 2002, Endocrine reviews.
[27] P. Vestergaard,et al. Effects of thiazide‐ and loop‐diuretics, alone or in combination, on calcitropic hormones and biochemical bone markers: a randomized controlled study , 2001, Journal of internal medicine.
[28] E. Siris,et al. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. , 1999, The New England journal of medicine.
[29] A. Stoll,et al. Alterations in parathyroid dynamics in lithium-treated subjects. , 1997, The Journal of clinical endocrinology and metabolism.
[30] E. Thurfjell,et al. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. , 1997, Surgery.
[31] H. Genant,et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. , 1995, The American journal of medicine.
[32] G. Kallner,et al. Renal, thyroid and parathyroid function during lithium treatment: laboratory tests in 207 people treated for 1–30 years , 1995, Acta psychiatrica Scandinavica.
[33] D. M. Tibbetts,et al. STUDIES OF CALCIUM AND PHOSPHORUS METABOLISM: XVIII. On Temporary Fluctuations in the Level of Calcium and Inorganic Phosphorus in Blood Serum of Normal Individuals. , 1931, The Journal of clinical investigation.
[34] M. Sargin,et al. Normocalcemic hyperparathyroidism and insulin resistance. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[35] R. Eastell,et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. , 2014, The Journal of clinical endocrinology and metabolism.
[36] R. Eastell,et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. , 2014, The Journal of clinical endocrinology and metabolism.
[37] S. Silverberg,et al. Normocalcemic primary hyperparathyroidism. , 2013, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.
[38] Alison M. MacLeod. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) , 2009 .
[39] R. Eastell,et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. , 2009, The Journal of clinical endocrinology and metabolism.
[40] Y. Greenman,et al. Characterization of normocalcemic primary hyperparathyroidism , 2007, Nature Clinical Practice Endocrinology &Metabolism.
[41] J. Firpo,et al. Evidence for secondary hyperparathyroidism in idiopathic hypercalciuria. , 1973, The Journal of clinical investigation.